Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device.

The CliniMACS CD34+ selection device was used for positive selection of apheresis products for autologous transplantation from 10 patients with malignant diseases and for allogeneic transplantation from 26 healthy donors. A total of 71 separations were performed. In 1 allogeneic donor, CD34+ progenitors were also isolated from bone marrow. Between 0.27 and 8.9 x 10(10) nucleated cells (median 4.9 x 10(10)) containing 0.09%-10.8% (median 0.67%) CD34+ progenitor cells were separated. After separation, a median number of 227 x 10(6) mononuclear cells (MNC) (51-524) were recovered, with a median viability of 99% (22%-100%) and a median purity of 97.0% (68.3%-99.7%) CD34+ cells. Depletion of T cells was extensive, with a median of 0.04% residual CD3+ cells (range <0.01%-0.92%). Residual CD19+ cells were between <0.01% and 17%, including CD34+CD19+ cells. Recovery of CD34+ cells was calculated according to the ISHAGE guidelines and ranged from 24% to 105% (median 71%). We conclude that with the CliniMACS device CD34+ cells with high purity and recovery can be isolated with concomitant effective T cell depletion in the allogeneic setting and with a high purging efficacy in the autologous setting.

[1]  R. Tedder,et al.  Extended routine polymerase chain reaction surveillance and pre‐emptive antiviral therapy for cytomegalovirus after allogeneic transplantation , 2000, British journal of haematology.

[2]  C. Huber,et al.  CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device. , 2000, Journal of hematotherapy & stem cell research.

[3]  I. Bechmann,et al.  Axonal Damage Induced by Invading T Cells in Organotypic Central Nervous System Tissue in vitro: Involvement of Microglial Cells , 2000, Brain pathology.

[4]  L. Berkahn.  State-of-the-Art Review: Immunologic Methods of Purging in Autologous Stem Cell Transplantation , 2000 .

[5]  T. Klingebiel,et al.  Isolation and transplantation of autologous peripheral CD34+ progenitor cells highly purified by magnetic-activated cell sorting , 1998, Bone Marrow Transplantation.

[6]  D. V. van Bockstaele,et al.  Analysis of variation in results of CD34+ hematopoietic progenitor cell enumeration in a multicenter study. , 1997, Cytometry.

[7]  T. Polyak,et al.  Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  A. Gratwohl,et al.  Blood and marrow stem cell transsplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) , 1997, Bone Marrow Transplantation.

[9]  I McNiece,et al.  Large-scale isolation of CD34+ cells using the Amgen cell selection device results in high levels of purity and recovery. , 1997, Journal of hematotherapy.

[10]  M. Okada,et al.  Second transplantation with CD34+ bone marrow cells selected from a two‐loci HLA‐mismatched sibling for a patient with chronic myeloid leukaemia , 1996, British journal of haematology.

[11]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[12]  S. Heimfeld,et al.  CD34+ progenitor cell selection: clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. , 1996, Journal of hematotherapy.

[13]  R. Champlin,et al.  Peripheral Blood Progenitor Cell Transplantation: A Replacement for Marrow Auto‐ or Allografts , 1996, Stem cells.

[14]  S. Kato,et al.  Successful engraftment of allogeneic CD34-enriched marrow cell transplantation from HLA-mismatched parental donors. , 1996, Bone marrow transplantation.

[15]  O. Bagasra,et al.  Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  F. Aversa,et al.  Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. , 1994, Blood.

[17]  Brochstein Ja.  Bone marrow transplantation for genetic disorders. , 1992 .

[18]  B. Dörken,et al.  Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. , 1997, Blood.

[19]  T. Luft,et al.  Comparison of purity and enrichment of CD34+ cells from bone marrow, umbilical cord and peripheral blood (primed for apheresis) using five separation systems , 1995, Stem cells.

[20]  B. Glass,et al.  The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment. , 1993, Bone marrow transplantation.